A CONTROLLED DOUBLE BLIND CLINICAL TRIAL OF BUSPIRONE AND DIAZEPAM IN GENERALISED ANXIETY DISORDER by Shah, L.P. et al.
Indian J. Psychiat. (1990), 32(2), 166-169 
A CONTROLLED DOUBLE BLIND CLINICAL TRIAL OF BUSPIRONE 
AND DIAZEPAM IN GENERALISED ANXIETY DISORDER 
L. P. SHAH
1, K. MAZUMDAR
2, S. R. PARKAR
3, P. R. GHODKE
4, 
». MANGALOAS
6, A. N. SHAH
5 
Buspirone hydrochloride is a now non-
benzodiazepine, non-barbiturate, non-nar-
cotic tranquilizer. It is an 'agaspirodecane-
dione", lipophilic and a heterocyclic com-
pound. 
Absorption of buspironc from gastroin-
testinal tract is virtually complete. Peak 
plasma level is achieved in less, than one 
hour after a single dose. The elimination 
half life of the drug ranges from 2 to 8 hours 
in healthy subjects and is significantly leng-
thened in renal and hepatic disease. Al-
though mechanism of the anxiolytic effect 
of buspirone is undetermined, complex 
interactions with several central nervous 
system neurotransmitters, especially seroto-
nin are thought to be contributory. Unlike 
benzodiazepine buspirone lacks hypnotic, 
anticonvulsant and muscle relaxant proper-
ties and has been termed anxio-selective 
(Eison and Temple, 1986; Skolnick et al., 
1985). 
In a few double blind clinical trials, bus-
pirone in 15-30 mg/day doses, improved 
symptoms of anxiety, assessed by standard 
rating scales, similar to diazepam and clora-
zepate (Cohn et al., 1986; Feighner et al., 
1982; Goldberg and Finnerty, 1979, 1982). 
Like diazepam, buspirone is effective in 
patients with mixed anxiety-depression 
(Feighner et al., 1982; Cohn et al., 1986). 
In healthy volunteers buspirone does 
not impair psychomotor or cognitive function 
(Smiley and Moskowitz, 1986). Because 
of its lack of euphoric effect, buspirone appears 
unlikely to become a drug of abuse (Cole 
ct al., 1982, Griffith et al., 1986). 
AIMS OF THE STUDY 
I. To compare the anxiolytic efficacy of 
buspirone and diazepam in treatment of 
patients suffering from generalized anxiety 
disorder. 
2. To evaluate safety and tolerability of 
buspirone in such patients. 
MATERIAL AND METHODOLOGY 
Patients suffering from generalised anxiety 
disorder according to DSM-III (APA, 1980) 
criteria were screened from the out-patient 
department. Specific inclusion and exclu-
sion criteria were used. 
On inclusion of patient in study, patients 
history, physical examination and rating on 
Hamilton Anxiety Rating Scale (HARS) 
were done. Basal lab investigations were 
also carried out. 
Patients were randomly distributed to 
two groups, Group A (Buspirone) and Group 
G (Diazepam). 
Both drugs were administered orally in 
the form of tablets, each tablet containing 
5 mg of the drug. The dosages used were 
15-45 mg/day, given in three divided dosage. 
The drugs were administered for a period 
of 4 weeks. Weekly assessment was done 
using:— 
(a) Patients and Physician's Global 
Impressions. 
(b) Physical examination and 
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(c) Hamilton Anxiety Rating Scale. 
At the end of 4 weeks basal lab investi-
gations were repeated. 
A total of 60 patients were included in 
.lie study with 30 patients in each group. 
The X
2 test and V test were employed for 
data analysis wherever applicable. 
Patients in both group were comparable 
in age sex and duration of illness. 
RESULTS AND DISCUSSION 
Table I shows the clinical improvement. 
In group A (buspirone) 16 completed the 4 
week study of whom 12 showed significant 
improvement. In drug group C (diazepam) 
21 completed the study of whom 16 showed 
significant improvement. 
Table II depicts the improvement in 
mean HARS scores reduction. There was 
64.24%, reduction in group A (buspirone) 
and 66.52% was in group C (diazepam). 
There was no significant difference in the two 
groups. In the buspirone group, the improve-
ment according to the HARS symptom pro-
file was in the cardio-vascular, symptoms, 
tension somatic (sensory) autonomic symp-
toms, anxious mood and insomnia while in 
the diazepam group, the improvement accor-
ding to the HARS symptom-profile was in 
the anxious mood, tension, insomnia, cogni-
tive symptoms, somatic (sensory), cardio-
vascular-symptoms and autonomic symptoms. 
However the mean total daily dosage required 
by the patients in the buspirone group was 
36.56 mg/day which is more than what has 
been reported (Goldberg and r'iimcriy, 1982; 
Pecknold et al., 1985; Riekels et ah, 1982). 
However, Fontain et al. (1987) reported 
diazepam to be significantly better than 
buspirone in reduction of anxiety. 
Table III shows the most common side 
effects observed in patients of both drug 
groups. Drowsiness and sedation were 
predominant in the diazepam group while 
buspirone group reported insomnia headache 
and C I. disturbances., which are similar 
to the reports of Riekels et al. (1982;, Nurton 
et al. (1982) and Colin and Wilcox (1982). Side 
effects observed in the patients who completed 
the study were however, of mild to moderate 
TABLE I. Clinical improvement 
Buspirone 
(n = 30) 
Diazepam 
(n = 30) 
Buspirone 
In = 16) 
Diazepam 
(,n=2l) 
Completed 
16 
21 
TABLE 11. 
Mean pre-treatment 
HARS score 
25 
24.70 
Less than 
50% reduction 
in HARS scores 
4 
5 
bnpmtment : HARS 
Mean post-
ircatment 
HARS score 
8.94 
8.29 
50-74% 
reduction in 
HARS scores 
7 
5 
SCOIti. 
o 
• o 
reduction 
64.24 
60. .12 
75",, & more 
reduction in 
HARS scores 
5 
11 
Mean total 
daily d<i»age 
at end of 
4 WWIM 
36.10 mg/day 
21.7) mg/day 168  L. P. SHAH ET AL. 
TABLF. III. Side ejects 
Buspirone Diazepam 
1. 
2. 
3. 
4. 
r>. 
<;. 
7. 
Insomnia 
Headache 
G. 1. disturbances 
Urticaria 
Giddiness 
Dryness of mouth 
Visual disturbances 
TABLF.  IV. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Drowsiness 
Sedation 
Dryness of moutlt 
Euphoria 
Giddiness 
Nausea/Vomi'ting 
Restlessness 
Dropouts 
1st week 2nd week 3rd week 4th week 
Buspirone 7 6 1 — 
(n=14) 
Diazepam 6 3 — — 
(n=9) 
intensity in both the groups. Laboratory 
investigations showed no abnormalities in 
both the groups. 
Table IV shows the patients who dropped 
out of the study. The dropout in the 1st 
week, was similar in both the groups with one 
patient of the diazepam group be
!ng with-
drawn due to pregnancy. 
However, more patients in the buspirone 
group (7) dropped out midway in the trial 
as compared to 3 in the diazepam group of 
whom 2 opting out due to drowsiness. No 
information is available about any of the 
drop-outs in the buspirone group. However, 
there was no difference in the mean pre-
treatment HARS scores of the patients who 
completed the study and those who dropped 
out, in either of the two groups. In this 
context, Pecknold et al. (1985) and Feighncr 
et al. (1982) noted a lag time of 1 to 2 weeks 
in the onset of anxiolytic effect of buspirone 
and hence motivation of the patient for bet-
ter compliance may be necessary. In this 
study of the 16 patients en the drug diazepam 
who showed significant improvement, at 
least 50% reduction in HARS scores, 8 im-
proved within 2 weeks, and 8 after 2 weeks; 
while of the 12 on the drug buspirone, who 
had significant improvement 2 improved 
within the 2nd week while as many as 10 
did so after 2 weeks. 
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